RxDoctor Payments Data

David Scadden

Hematology & Oncology · Boston, MANPI 1609829852

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,347,081 of the $2,607,960 with a category attached, or 90.0%. Agios Pharmaceuticals, Inc. accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,607,960in general payments, 2019–2025

Across 50 payments — averaging $52,159 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Agios Pharmaceuticals, Inc.$2.6M
  • AstraZeneca$3K
$975in research payments, 2019–2025

Across 1 payment — averaging $975.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$975

What the payments were for

  • Consulting fees$260,55910%
  • Speaking & faculty fees$2,347,08190%
  • Travel & lodging$1700%
  • Food & beverage$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Agios Pharmaceuticals, Inc.48$2,605,360
AstraZeneca2$2,600

How this compares

$2,607,960 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Other hematology & oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →